H. Lee Moffitt Cancer Center

Delineation of Immune Evasive Mechanisms Driving Poor Outcome in TP53 Mutant Myelodysplatic Syndromes


The Vera and Joseph Dresner Foundation granted H Lee Moffitt Cancer Center a $250,000 grant for early career investigator Dr. David A. Sallman.


The goal of the research project is to (1) establish TP53 gene as a predictor of outcomes for patients with this mutation; and (2) to identify the underlying reasons why TP53 mutant patients frequently have poor response to treatments.

Learn more about H. Lee Moffitt Cancer Center